TRAX: Advancing dual-mechanism CD122 therapy in celiac and EoE, with key data and expansion ahead
The company, newly formed and well-funded, is advancing a pipeline led by ANB033, a dual-mechanism CD122 antagonist targeting autoimmune diseases, with phase I-B trials in celiac disease and EoE. Data readouts are expected over the next year, with plans for further indication expansion and a focus…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.